| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Weight Loss | 47 | 2024 | 481 | 9.170 |
Why?
|
| Obesity | 61 | 2025 | 2235 | 8.910 |
Why?
|
| Exercise | 53 | 2025 | 814 | 8.120 |
Why?
|
| Bone Density | 46 | 2024 | 316 | 7.320 |
Why?
|
| Caloric Restriction | 32 | 2023 | 85 | 7.280 |
Why?
|
| Frail Elderly | 19 | 2022 | 94 | 4.480 |
Why?
|
| Sarcopenia | 13 | 2025 | 39 | 4.380 |
Why?
|
| Life Style | 17 | 2025 | 406 | 3.980 |
Why?
|
| Exercise Therapy | 17 | 2025 | 152 | 3.980 |
Why?
|
| Diet, Reducing | 14 | 2022 | 90 | 3.790 |
Why?
|
| Aging | 25 | 2025 | 1185 | 3.300 |
Why?
|
| Body Composition | 34 | 2024 | 516 | 3.250 |
Why?
|
| Testosterone | 16 | 2025 | 532 | 3.140 |
Why?
|
| Hypogonadism | 14 | 2025 | 281 | 3.110 |
Why?
|
| Resistance Training | 7 | 2022 | 32 | 2.980 |
Why?
|
| Aged | 99 | 2025 | 19194 | 2.470 |
Why?
|
| Hormone Replacement Therapy | 10 | 2025 | 195 | 2.370 |
Why?
|
| Muscle, Skeletal | 16 | 2022 | 941 | 2.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2024 | 1237 | 1.960 |
Why?
|
| Overweight | 7 | 2019 | 358 | 1.870 |
Why?
|
| Oxygen Consumption | 17 | 2021 | 307 | 1.650 |
Why?
|
| Bone and Bones | 9 | 2022 | 262 | 1.590 |
Why?
|
| Dehydroepiandrosterone | 8 | 2018 | 16 | 1.560 |
Why?
|
| Bone Remodeling | 10 | 2021 | 56 | 1.550 |
Why?
|
| Osteoporosis | 9 | 2021 | 116 | 1.550 |
Why?
|
| Body Mass Index | 27 | 2023 | 1553 | 1.500 |
Why?
|
| Incretins | 3 | 2024 | 25 | 1.330 |
Why?
|
| Muscle Strength | 8 | 2020 | 75 | 1.330 |
Why?
|
| Intra-Abdominal Fat | 4 | 2022 | 51 | 1.330 |
Why?
|
| Insulin | 12 | 2017 | 1208 | 1.330 |
Why?
|
| Muscle Proteins | 6 | 2019 | 418 | 1.310 |
Why?
|
| Insulin Resistance | 10 | 2025 | 644 | 1.280 |
Why?
|
| Quality of Life | 13 | 2025 | 1933 | 1.200 |
Why?
|
| Cognition | 6 | 2022 | 738 | 1.200 |
Why?
|
| Humans | 152 | 2025 | 123258 | 1.190 |
Why?
|
| Male | 113 | 2025 | 60336 | 1.160 |
Why?
|
| Fractures, Bone | 4 | 2023 | 187 | 1.140 |
Why?
|
| Diet | 13 | 2021 | 1136 | 1.000 |
Why?
|
| Hip | 5 | 2012 | 20 | 1.000 |
Why?
|
| Combined Modality Therapy | 10 | 2025 | 1239 | 0.990 |
Why?
|
| C-Reactive Protein | 9 | 2023 | 406 | 0.980 |
Why?
|
| Physical Fitness | 5 | 2012 | 91 | 0.960 |
Why?
|
| Frailty | 3 | 2022 | 98 | 0.960 |
Why?
|
| Body Weight | 15 | 2017 | 1007 | 0.960 |
Why?
|
| Energy Intake | 14 | 2023 | 490 | 0.930 |
Why?
|
| Female | 99 | 2025 | 65619 | 0.870 |
Why?
|
| Blood Glucose | 16 | 2015 | 1123 | 0.850 |
Why?
|
| Aged, 80 and over | 24 | 2025 | 6392 | 0.840 |
Why?
|
| Healthy Aging | 2 | 2025 | 8 | 0.840 |
Why?
|
| Metabolic Syndrome | 5 | 2021 | 329 | 0.830 |
Why?
|
| Osteocalcin | 6 | 2022 | 42 | 0.800 |
Why?
|
| Physical Endurance | 7 | 2017 | 45 | 0.760 |
Why?
|
| Cellular Senescence | 1 | 2023 | 161 | 0.750 |
Why?
|
| Adiponectin | 4 | 2016 | 109 | 0.750 |
Why?
|
| Estradiol | 6 | 2022 | 544 | 0.720 |
Why?
|
| Leptin | 5 | 2022 | 214 | 0.710 |
Why?
|
| Adiposity | 6 | 2022 | 191 | 0.710 |
Why?
|
| Double-Blind Method | 9 | 2025 | 1601 | 0.700 |
Why?
|
| Absorptiometry, Photon | 13 | 2022 | 179 | 0.690 |
Why?
|
| Glucose Tolerance Test | 12 | 2019 | 209 | 0.690 |
Why?
|
| Middle Aged | 60 | 2025 | 26087 | 0.690 |
Why?
|
| Behavior Therapy | 2 | 2021 | 255 | 0.680 |
Why?
|
| Sex Hormone-Binding Globulin | 3 | 2017 | 38 | 0.640 |
Why?
|
| Healthy Lifestyle | 1 | 2019 | 31 | 0.620 |
Why?
|
| Adipose Tissue | 8 | 2020 | 465 | 0.620 |
Why?
|
| Osteoporosis, Postmenopausal | 5 | 2007 | 24 | 0.620 |
Why?
|
| Cardiovascular Diseases | 5 | 2020 | 1877 | 0.590 |
Why?
|
| Lumbar Vertebrae | 4 | 2018 | 109 | 0.590 |
Why?
|
| Activities of Daily Living | 5 | 2014 | 404 | 0.590 |
Why?
|
| Adjuvants, Immunologic | 3 | 2006 | 375 | 0.550 |
Why?
|
| Serum Amyloid P-Component | 1 | 2016 | 13 | 0.540 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2003 | 44 | 0.540 |
Why?
|
| Fasting | 2 | 2023 | 300 | 0.530 |
Why?
|
| Insulin-Like Growth Factor I | 8 | 2015 | 342 | 0.520 |
Why?
|
| Vitamin D | 5 | 2022 | 159 | 0.500 |
Why?
|
| Biomarkers | 13 | 2024 | 2952 | 0.490 |
Why?
|
| Energy Metabolism | 8 | 2020 | 774 | 0.450 |
Why?
|
| Vitamin K Deficiency | 1 | 2014 | 3 | 0.450 |
Why?
|
| Vitamin K | 1 | 2014 | 35 | 0.440 |
Why?
|
| Inflammation | 5 | 2023 | 1405 | 0.440 |
Why?
|
| Hormones | 2 | 2011 | 190 | 0.420 |
Why?
|
| Motor Activity | 2 | 2015 | 522 | 0.420 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2003 | 16 | 0.410 |
Why?
|
| Precision Medicine | 1 | 2015 | 308 | 0.410 |
Why?
|
| Adult | 36 | 2025 | 29100 | 0.400 |
Why?
|
| Coronary Disease | 4 | 2020 | 637 | 0.400 |
Why?
|
| Glucose Intolerance | 2 | 2012 | 77 | 0.400 |
Why?
|
| Phentermine | 1 | 2011 | 7 | 0.380 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2012 | 125 | 0.370 |
Why?
|
| Cross-Sectional Studies | 11 | 2023 | 3383 | 0.370 |
Why?
|
| Anti-Obesity Agents | 1 | 2011 | 42 | 0.360 |
Why?
|
| Protein Biosynthesis | 2 | 2011 | 665 | 0.360 |
Why?
|
| Longevity | 3 | 2025 | 138 | 0.360 |
Why?
|
| Gastric Inhibitory Polypeptide | 3 | 2016 | 19 | 0.360 |
Why?
|
| Collagen Type I | 7 | 2022 | 111 | 0.360 |
Why?
|
| Fructose | 1 | 2011 | 62 | 0.350 |
Why?
|
| Feeding Behavior | 2 | 2014 | 707 | 0.350 |
Why?
|
| TCF Transcription Factors | 1 | 2009 | 17 | 0.340 |
Why?
|
| Glucagon-Like Peptide 1 | 2 | 2024 | 68 | 0.340 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 623 | 0.340 |
Why?
|
| Blood Pressure | 12 | 2019 | 1326 | 0.330 |
Why?
|
| KATP Channels | 1 | 2009 | 6 | 0.330 |
Why?
|
| Health Promotion | 3 | 2021 | 390 | 0.330 |
Why?
|
| Postmenopause | 3 | 2020 | 125 | 0.330 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 1 | 2009 | 34 | 0.320 |
Why?
|
| Osteoblasts | 2 | 2025 | 149 | 0.320 |
Why?
|
| Gait | 4 | 2017 | 146 | 0.310 |
Why?
|
| Glucose | 5 | 2022 | 880 | 0.310 |
Why?
|
| Treatment Outcome | 11 | 2025 | 12169 | 0.300 |
Why?
|
| Risk Factors | 15 | 2021 | 10035 | 0.300 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 2525 | 0.300 |
Why?
|
| C-Peptide | 4 | 2015 | 113 | 0.290 |
Why?
|
| Aromatase | 2 | 2019 | 22 | 0.290 |
Why?
|
| Fatty Liver | 1 | 2009 | 178 | 0.290 |
Why?
|
| Soybean Proteins | 1 | 2007 | 18 | 0.280 |
Why?
|
| Islets of Langerhans | 1 | 2008 | 173 | 0.280 |
Why?
|
| Isoflavones | 1 | 2007 | 44 | 0.270 |
Why?
|
| Missouri | 2 | 2016 | 36 | 0.270 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 3 | 2015 | 31 | 0.270 |
Why?
|
| Abdominal Fat | 3 | 2015 | 19 | 0.270 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2003 | 18 | 0.260 |
Why?
|
| Dietary Proteins | 4 | 2019 | 245 | 0.260 |
Why?
|
| Alkaline Phosphatase | 4 | 2010 | 98 | 0.260 |
Why?
|
| Triglycerides | 3 | 2022 | 562 | 0.260 |
Why?
|
| DNA-Binding Proteins | 2 | 2025 | 2054 | 0.260 |
Why?
|
| Genetic Variation | 2 | 2009 | 1479 | 0.260 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 5056 | 0.250 |
Why?
|
| Adaptation, Physiological | 6 | 2015 | 261 | 0.250 |
Why?
|
| Transcription Factors | 3 | 2025 | 2586 | 0.250 |
Why?
|
| Diet, Vegetarian | 1 | 2005 | 5 | 0.250 |
Why?
|
| Peptides | 6 | 2017 | 791 | 0.250 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2025 | 9 | 0.240 |
Why?
|
| Interleukin-6 | 4 | 2014 | 395 | 0.240 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2024 | 17 | 0.240 |
Why?
|
| Estrogens | 6 | 2004 | 512 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2022 | 1080 | 0.240 |
Why?
|
| Sex Factors | 5 | 2023 | 1265 | 0.230 |
Why?
|
| Dehydroepiandrosterone Sulfate | 2 | 2020 | 17 | 0.230 |
Why?
|
| Risk | 2 | 2016 | 747 | 0.220 |
Why?
|
| Finite Element Analysis | 1 | 2023 | 28 | 0.220 |
Why?
|
| Hand Strength | 1 | 2023 | 41 | 0.220 |
Why?
|
| Progesterone Congeners | 1 | 2003 | 8 | 0.220 |
Why?
|
| Weight Reduction Programs | 2 | 2021 | 57 | 0.220 |
Why?
|
| Muscle Weakness | 1 | 2004 | 84 | 0.220 |
Why?
|
| beta Catenin | 1 | 2025 | 205 | 0.220 |
Why?
|
| Vascular Stiffness | 2 | 2016 | 75 | 0.220 |
Why?
|
| Wnt Signaling Pathway | 1 | 2025 | 196 | 0.220 |
Why?
|
| Biology | 1 | 2023 | 29 | 0.210 |
Why?
|
| Time Factors | 11 | 2019 | 6222 | 0.210 |
Why?
|
| Health Status | 3 | 2017 | 375 | 0.210 |
Why?
|
| Weight Gain | 2 | 2024 | 400 | 0.200 |
Why?
|
| Independent Living | 1 | 2022 | 65 | 0.190 |
Why?
|
| Nutritional Requirements | 2 | 2014 | 181 | 0.190 |
Why?
|
| Proteins | 2 | 2023 | 1040 | 0.190 |
Why?
|
| Adipocytes | 2 | 2020 | 158 | 0.180 |
Why?
|
| Bronchitis, Chronic | 1 | 2021 | 18 | 0.180 |
Why?
|
| Patient Compliance | 4 | 2016 | 470 | 0.180 |
Why?
|
| Hyperglycemia | 1 | 2022 | 222 | 0.180 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 429 | 0.170 |
Why?
|
| STAT1 Transcription Factor | 1 | 2020 | 69 | 0.170 |
Why?
|
| Thigh | 2 | 2013 | 50 | 0.170 |
Why?
|
| Femur Neck | 1 | 2019 | 9 | 0.170 |
Why?
|
| Oxidative Stress | 3 | 2023 | 796 | 0.170 |
Why?
|
| Pulmonary Emphysema | 1 | 2021 | 94 | 0.170 |
Why?
|
| Hydrocortisone | 3 | 2016 | 220 | 0.170 |
Why?
|
| Prospective Studies | 8 | 2022 | 6030 | 0.160 |
Why?
|
| Pilot Projects | 3 | 2020 | 1389 | 0.160 |
Why?
|
| Elder Nutritional Physiological Phenomena | 1 | 2019 | 2 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2018 | 3336 | 0.160 |
Why?
|
| Calcium, Dietary | 1 | 2019 | 37 | 0.160 |
Why?
|
| Spine | 2 | 2006 | 143 | 0.160 |
Why?
|
| Exercise Test | 4 | 2017 | 249 | 0.160 |
Why?
|
| Cytokines | 2 | 2016 | 1282 | 0.150 |
Why?
|
| United States | 6 | 2021 | 10652 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2016 | 3549 | 0.150 |
Why?
|
| Reference Values | 2 | 2009 | 701 | 0.150 |
Why?
|
| Comorbidity | 2 | 2018 | 1497 | 0.150 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 130 | 0.150 |
Why?
|
| Femur | 3 | 2018 | 65 | 0.140 |
Why?
|
| Insulin-Secreting Cells | 2 | 2009 | 147 | 0.140 |
Why?
|
| Body Fluid Compartments | 1 | 2017 | 18 | 0.140 |
Why?
|
| Physical Conditioning, Human | 1 | 2017 | 2 | 0.140 |
Why?
|
| Postprandial Period | 2 | 2015 | 77 | 0.140 |
Why?
|
| Illinois | 1 | 2016 | 15 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2017 | 235 | 0.130 |
Why?
|
| Alzheimer Disease | 1 | 2003 | 765 | 0.130 |
Why?
|
| Genotype | 4 | 2009 | 2537 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1084 | 0.130 |
Why?
|
| Menopause | 3 | 2004 | 75 | 0.130 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 667 | 0.130 |
Why?
|
| Mobility Limitation | 1 | 2015 | 25 | 0.130 |
Why?
|
| Antibodies, Blocking | 1 | 2016 | 61 | 0.130 |
Why?
|
| Diet Therapy | 1 | 2016 | 42 | 0.130 |
Why?
|
| Ventricular Function, Left | 4 | 2007 | 496 | 0.120 |
Why?
|
| Feasibility Studies | 3 | 2015 | 754 | 0.120 |
Why?
|
| Calcitonin | 2 | 1992 | 31 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2008 | 1012 | 0.120 |
Why?
|
| Time | 2 | 2017 | 94 | 0.120 |
Why?
|
| Muscular Atrophy | 1 | 2016 | 74 | 0.120 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 77 | 0.120 |
Why?
|
| Depression | 1 | 2023 | 1230 | 0.120 |
Why?
|
| Troponin T | 1 | 2016 | 245 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 1 | 2018 | 454 | 0.120 |
Why?
|
| RNA | 2 | 2008 | 570 | 0.120 |
Why?
|
| Walking | 1 | 2017 | 210 | 0.120 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 139 | 0.120 |
Why?
|
| Animals | 9 | 2023 | 33847 | 0.120 |
Why?
|
| Endocrine Glands | 1 | 1994 | 10 | 0.120 |
Why?
|
| Nitric Oxide Synthase | 1 | 1995 | 187 | 0.120 |
Why?
|
| Bone Resorption | 3 | 2008 | 41 | 0.110 |
Why?
|
| Collagen | 3 | 2005 | 317 | 0.110 |
Why?
|
| Calcium | 4 | 2009 | 1098 | 0.110 |
Why?
|
| Research Design | 1 | 2018 | 679 | 0.110 |
Why?
|
| Myostatin | 1 | 2013 | 19 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2017 | 1315 | 0.110 |
Why?
|
| Asthma | 1 | 2021 | 744 | 0.110 |
Why?
|
| Hip Joint | 1 | 2013 | 38 | 0.110 |
Why?
|
| Cognitive Dysfunction | 1 | 2017 | 226 | 0.110 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1993 | 28 | 0.110 |
Why?
|
| Triiodothyronine | 2 | 2015 | 64 | 0.110 |
Why?
|
| Age Factors | 5 | 2020 | 2811 | 0.110 |
Why?
|
| Leucine | 2 | 2011 | 310 | 0.110 |
Why?
|
| Nutrition Policy | 1 | 2014 | 100 | 0.110 |
Why?
|
| Calcitriol | 1 | 1993 | 81 | 0.100 |
Why?
|
| RNA, Messenger | 4 | 2016 | 2815 | 0.100 |
Why?
|
| Osteosclerosis | 1 | 1992 | 12 | 0.100 |
Why?
|
| Up-Regulation | 2 | 2012 | 862 | 0.100 |
Why?
|
| Interleukin-1 | 1 | 1993 | 143 | 0.100 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1992 | 39 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2016 | 747 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2024 | 4499 | 0.100 |
Why?
|
| Neurotensin | 1 | 2012 | 4 | 0.100 |
Why?
|
| Acids | 1 | 2012 | 28 | 0.100 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2009 | 55 | 0.100 |
Why?
|
| Placebos | 2 | 2011 | 241 | 0.100 |
Why?
|
| Linear Models | 1 | 2014 | 669 | 0.100 |
Why?
|
| Knee Joint | 1 | 2013 | 160 | 0.100 |
Why?
|
| Area Under Curve | 3 | 2008 | 314 | 0.100 |
Why?
|
| Organ Size | 3 | 2012 | 419 | 0.100 |
Why?
|
| Glucagon | 2 | 2012 | 185 | 0.100 |
Why?
|
| Mass Screening | 1 | 2018 | 787 | 0.100 |
Why?
|
| Prevalence | 1 | 2018 | 2409 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2014 | 268 | 0.100 |
Why?
|
| Surveys and Questionnaires | 3 | 2013 | 3677 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 2844 | 0.100 |
Why?
|
| Tibia | 2 | 2022 | 70 | 0.090 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 560 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 2 | 2015 | 20 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 340 | 0.090 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 58 | 0.090 |
Why?
|
| Blood Chemical Analysis | 2 | 2011 | 78 | 0.090 |
Why?
|
| Delayed-Action Preparations | 1 | 2011 | 110 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2012 | 606 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2011 | 268 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 810 | 0.090 |
Why?
|
| Heart Failure | 3 | 2020 | 2131 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2011 | 772 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2014 | 475 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 1991 | 71 | 0.080 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2009 | 24 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 1009 | 0.080 |
Why?
|
| Sulfonylurea Receptors | 1 | 2009 | 13 | 0.080 |
Why?
|
| Receptors, Drug | 1 | 2009 | 38 | 0.080 |
Why?
|
| Glucose Clamp Technique | 1 | 2009 | 79 | 0.080 |
Why?
|
| Models, Biological | 2 | 2011 | 1449 | 0.080 |
Why?
|
| Polymorphism, Genetic | 2 | 2019 | 807 | 0.080 |
Why?
|
| Osteitis | 1 | 2008 | 1 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 529 | 0.080 |
Why?
|
| Arthropathy, Neurogenic | 1 | 2008 | 3 | 0.080 |
Why?
|
| Osteolysis | 1 | 2008 | 9 | 0.080 |
Why?
|
| Protein Deficiency | 1 | 2008 | 20 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 1991 | 378 | 0.080 |
Why?
|
| Anaerobic Threshold | 1 | 2008 | 11 | 0.080 |
Why?
|
| Intestinal Absorption | 2 | 2008 | 190 | 0.080 |
Why?
|
| Dietary Sucrose | 1 | 2008 | 41 | 0.080 |
Why?
|
| Sex Characteristics | 4 | 2015 | 314 | 0.080 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2009 | 186 | 0.070 |
Why?
|
| Amino Acids | 2 | 2009 | 663 | 0.070 |
Why?
|
| Diabetic Neuropathies | 1 | 2008 | 58 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 393 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 1703 | 0.070 |
Why?
|
| Parathyroid Hormone | 2 | 2022 | 72 | 0.070 |
Why?
|
| Muscular Diseases | 1 | 2008 | 102 | 0.070 |
Why?
|
| Radioisotopes | 1 | 2007 | 38 | 0.070 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2007 | 77 | 0.070 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2008 | 143 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1689 | 0.070 |
Why?
|
| Transcriptome | 1 | 2013 | 903 | 0.070 |
Why?
|
| Leukocytes | 1 | 2008 | 206 | 0.070 |
Why?
|
| Prognosis | 3 | 2020 | 4510 | 0.070 |
Why?
|
| Biopsy | 2 | 2009 | 1236 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 233 | 0.070 |
Why?
|
| Heart Rate | 5 | 2012 | 587 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 281 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2009 | 337 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 2586 | 0.070 |
Why?
|
| Arteries | 2 | 2004 | 222 | 0.070 |
Why?
|
| Weight-Bearing | 2 | 2021 | 45 | 0.070 |
Why?
|
| Advisory Committees | 2 | 2018 | 148 | 0.060 |
Why?
|
| Women's Health | 1 | 2007 | 132 | 0.060 |
Why?
|
| Diabetic Foot | 1 | 2008 | 156 | 0.060 |
Why?
|
| New Mexico | 2 | 2017 | 6 | 0.060 |
Why?
|
| Muscle Contraction | 1 | 2006 | 186 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 268 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 1289 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 516 | 0.060 |
Why?
|
| Patient Selection | 1 | 2009 | 683 | 0.060 |
Why?
|
| Pregnancy Proteins | 1 | 2005 | 13 | 0.060 |
Why?
|
| Lipids | 2 | 2015 | 513 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 577 | 0.060 |
Why?
|
| Waist Circumference | 2 | 2017 | 88 | 0.060 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2004 | 82 | 0.060 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 424 | 0.060 |
Why?
|
| Stroke Volume | 2 | 2003 | 446 | 0.060 |
Why?
|
| Abdomen | 1 | 2004 | 129 | 0.060 |
Why?
|
| Lipid Metabolism | 1 | 2006 | 349 | 0.060 |
Why?
|
| Wnt Proteins | 1 | 2025 | 196 | 0.060 |
Why?
|
| Basal Metabolism | 2 | 2015 | 93 | 0.060 |
Why?
|
| Osteogenesis | 1 | 2025 | 154 | 0.060 |
Why?
|
| Smoking | 1 | 2009 | 1031 | 0.050 |
Why?
|
| Rome | 1 | 2023 | 7 | 0.050 |
Why?
|
| Young Adult | 4 | 2019 | 8868 | 0.050 |
Why?
|
| Italy | 1 | 2023 | 111 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2025 | 2058 | 0.050 |
Why?
|
| Postural Balance | 1 | 2004 | 125 | 0.050 |
Why?
|
| DNA | 1 | 2008 | 1594 | 0.050 |
Why?
|
| Demography | 1 | 2003 | 239 | 0.050 |
Why?
|
| Osteoclasts | 1 | 2022 | 52 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2022 | 197 | 0.050 |
Why?
|
| Radiography | 3 | 1992 | 822 | 0.050 |
Why?
|
| Consensus | 1 | 2025 | 610 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2025 | 547 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2025 | 378 | 0.050 |
Why?
|
| Receptors, Interferon | 1 | 2020 | 25 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 98 | 0.040 |
Why?
|
| Dietary Carbohydrates | 2 | 2014 | 118 | 0.040 |
Why?
|
| Leadership | 1 | 2023 | 226 | 0.040 |
Why?
|
| Network Meta-Analysis | 1 | 2020 | 29 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2021 | 195 | 0.040 |
Why?
|
| Calorimetry, Indirect | 2 | 2012 | 60 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2020 | 76 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2003 | 1473 | 0.040 |
Why?
|
| Lipoproteins | 1 | 2000 | 177 | 0.040 |
Why?
|
| Psychometrics | 1 | 2003 | 666 | 0.040 |
Why?
|
| Musculoskeletal System | 1 | 2019 | 18 | 0.040 |
Why?
|
| Base Sequence | 2 | 1995 | 3091 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 290 | 0.040 |
Why?
|
| Blood Flow Velocity | 2 | 2012 | 449 | 0.040 |
Why?
|
| Pelvic Bones | 1 | 2018 | 27 | 0.040 |
Why?
|
| RNA Interference | 1 | 2020 | 496 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 3867 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2020 | 499 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 4367 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2019 | 256 | 0.040 |
Why?
|
| Androgens | 1 | 2020 | 274 | 0.040 |
Why?
|
| Metabolome | 1 | 2020 | 294 | 0.040 |
Why?
|
| Heart | 1 | 2002 | 723 | 0.040 |
Why?
|
| Disease Progression | 1 | 2003 | 2030 | 0.040 |
Why?
|
| Torso | 1 | 2017 | 12 | 0.040 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 54 | 0.030 |
Why?
|
| Lung | 1 | 2025 | 1465 | 0.030 |
Why?
|
| Apolipoprotein E4 | 1 | 2017 | 43 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 169 | 0.030 |
Why?
|
| Prostate | 1 | 2019 | 431 | 0.030 |
Why?
|
| Homeostasis | 1 | 2020 | 682 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 115 | 0.030 |
Why?
|
| Beclin-1 | 1 | 2016 | 26 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 133 | 0.030 |
Why?
|
| Walk Test | 1 | 2016 | 24 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2016 | 68 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 270 | 0.030 |
Why?
|
| Mice | 3 | 2020 | 17552 | 0.030 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1995 | 14 | 0.030 |
Why?
|
| Diastole | 2 | 2007 | 168 | 0.030 |
Why?
|
| Sodium, Dietary | 1 | 1995 | 35 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2016 | 151 | 0.030 |
Why?
|
| Physical Education and Training | 2 | 2005 | 20 | 0.030 |
Why?
|
| Body Temperature | 1 | 2015 | 113 | 0.030 |
Why?
|
| Mice, Obese | 1 | 1995 | 78 | 0.030 |
Why?
|
| Heat-Shock Proteins | 1 | 2016 | 194 | 0.030 |
Why?
|
| Hip Fractures | 1 | 2016 | 67 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 400 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2016 | 288 | 0.030 |
Why?
|
| Kidney Glomerulus | 1 | 1995 | 80 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 244 | 0.030 |
Why?
|
| Mastication | 1 | 2014 | 6 | 0.030 |
Why?
|
| Snacks | 1 | 2014 | 19 | 0.030 |
Why?
|
| Edible Grain | 1 | 2014 | 45 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 619 | 0.030 |
Why?
|
| Thyroid Hormones | 1 | 1994 | 66 | 0.030 |
Why?
|
| Growth Substances | 1 | 1994 | 113 | 0.030 |
Why?
|
| Dietary Fiber | 1 | 2014 | 74 | 0.030 |
Why?
|
| Premenopause | 1 | 1993 | 31 | 0.030 |
Why?
|
| Ascorbic Acid | 1 | 2014 | 78 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 660 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2016 | 364 | 0.030 |
Why?
|
| Mitochondrial Turnover | 1 | 2013 | 3 | 0.030 |
Why?
|
| Quadriceps Muscle | 1 | 2013 | 12 | 0.030 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2013 | 25 | 0.030 |
Why?
|
| 3T3 Cells | 1 | 1993 | 129 | 0.030 |
Why?
|
| Cardiac Output | 2 | 2004 | 169 | 0.030 |
Why?
|
| Hypothalamus | 1 | 1995 | 217 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1993 | 183 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1993 | 259 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 143 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2020 | 3726 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2014 | 296 | 0.020 |
Why?
|
| Osteitis Deformans | 1 | 1992 | 7 | 0.020 |
Why?
|
| Anemia | 1 | 2016 | 341 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1994 | 316 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2014 | 305 | 0.020 |
Why?
|
| Lysine | 1 | 1992 | 198 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2016 | 489 | 0.020 |
Why?
|
| Antibodies | 1 | 1993 | 371 | 0.020 |
Why?
|
| Hydroxycholecalciferols | 1 | 1991 | 6 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 4227 | 0.020 |
Why?
|
| Echocardiography | 2 | 2007 | 1049 | 0.020 |
Why?
|
| Hepacivirus | 1 | 1992 | 241 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 365 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 1245 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1006 | 0.020 |
Why?
|
| Rats | 2 | 2013 | 3666 | 0.020 |
Why?
|
| Keto Acids | 1 | 2009 | 56 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1992 | 768 | 0.020 |
Why?
|
| Phenylalanine | 1 | 2009 | 124 | 0.020 |
Why?
|
| Veterans | 1 | 2021 | 1737 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 1385 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 1992 | 668 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2009 | 116 | 0.020 |
Why?
|
| Pain | 1 | 1992 | 470 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2009 | 59 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 594 | 0.020 |
Why?
|
| Skin Temperature | 1 | 2008 | 19 | 0.020 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2008 | 10 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 2008 | 7 | 0.020 |
Why?
|
| Memory | 1 | 2012 | 363 | 0.020 |
Why?
|
| Urine | 1 | 2008 | 89 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 539 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2008 | 51 | 0.020 |
Why?
|
| Diet Records | 1 | 2008 | 74 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2008 | 52 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1284 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2016 | 1523 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 926 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1318 | 0.020 |
Why?
|
| Computers | 1 | 2007 | 67 | 0.020 |
Why?
|
| Vasodilation | 1 | 2008 | 191 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 444 | 0.020 |
Why?
|
| Anthropometry | 1 | 2007 | 198 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2007 | 105 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 311 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 170 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2006 | 136 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 1992 | 1139 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 488 | 0.020 |
Why?
|
| Aerobiosis | 1 | 2005 | 14 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 110 | 0.010 |
Why?
|
| Lower Extremity | 1 | 2006 | 183 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2007 | 471 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 143 | 0.010 |
Why?
|
| Elasticity | 1 | 2004 | 92 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 261 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2008 | 1611 | 0.010 |
Why?
|
| Rest | 1 | 2003 | 58 | 0.010 |
Why?
|
| Systole | 1 | 2003 | 196 | 0.010 |
Why?
|
| Software | 1 | 2007 | 675 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2019 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 3239 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2002 | 260 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 2854 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 1602 | 0.010 |
Why?
|
| Dihydropyridines | 1 | 1995 | 8 | 0.010 |
Why?
|
| Nitrobenzenes | 1 | 1995 | 16 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 1995 | 64 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1992 | 16068 | 0.010 |
Why?
|
| Angiotensin II | 1 | 1995 | 161 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1995 | 173 | 0.010 |
Why?
|
| Piperazines | 1 | 1995 | 229 | 0.010 |
Why?
|
| Biological Availability | 1 | 1992 | 133 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1992 | 151 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 1995 | 396 | 0.010 |
Why?
|